This company listing is no longer active
VectivBio Holding Past Earnings Performance
Past criteria checks 0/6
VectivBio Holding's earnings have been declining at an average annual rate of -24.4%, while the Biotechs industry saw earnings growing at 32.7% annually. Revenues have been growing at an average rate of 120.3% per year.
Key information
-24.4%
Earnings growth rate
25.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 120.3% |
| Return on equity | -43.9% |
| Net Margin | -342.8% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How VectivBio Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 27 | -94 | 34 | 74 |
| 30 Sep 22 | 27 | -83 | 34 | 71 |
| 30 Jun 22 | 26 | -72 | 37 | 68 |
| 31 Mar 22 | 13 | -80 | 37 | 63 |
| 31 Dec 21 | 0 | -87 | 36 | 57 |
| 30 Sep 21 | 0 | -87 | 32 | 51 |
| 30 Jun 21 | 0 | -87 | 28 | 46 |
| 31 Mar 21 | 0 | -74 | 21 | 38 |
| 31 Dec 20 | 0 | -60 | 14 | 30 |
Quality Earnings: VECT is currently unprofitable.
Growing Profit Margin: VECT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if VECT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare VECT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VECT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-43.2%).
Return on Equity
High ROE: VECT has a negative Return on Equity (-43.93%), as it is currently unprofitable.